1 Penny Stock That Could Howl Its Way to the Top After a $150 Million Funding Boost

Werewolf Therapeutics (HOWL) is a clinical-stage biotech firm pioneering immune-activating cancer and immune-mediated disorder therapies. The stock has soared 50% YTD and over 133% in the past five days. Two factors have fueled this rally: a proposed merger with Ambros Therapeutics and a $150 million private placement. Ambros brings its late-stage pipeline, including a potential CRPS-1 treatment in a pivotal Phase 3 trial, to the combined company.

Werewolf's oncology programs and the merger's funding extend the combined company's cash runway through the first half of 2029. However, investors should be aware of the risks associated with penny stocks and the uncertainties surrounding merger approvals and clinical trial outcomes.